Innovation in Antibacterial Treatments
As we gradually recover from the pandemic, there is an increased recognition of the severe impact of infectious diseases. In 2019, it is estimated that over 1.2 million people globally died due to the rapid rise of bacterial antibiotic resistance, a number that could escalate to 10 million annually by 2050 if no preventive measures are taken. Fortunately, numerous public and private organizations are actively engaged in creating new drugs and therapies to combat antimicrobial resistance, with assistance from government bodies, non-profit organizations, academic institutions, and major pharmaceutical companies such as Pfizer, GSK, and Novo Nordisk. This 40-page report profiles 122 companies that are working on antibacterial solutions, including Accelerate Diagnostics, Selux Diagnostics, Day Zero Diagnostics, GenomeKey, Karius, Otsuka Pharmaceutical Companies, Basilea Pharmaceutica, Nosopharm, Omnix Medical, Peptilogics, Adaptive Phage Therapeutics, Locus Biosciences, Phico Therapeutics, Seres Therapeutics, Enterome, Eligo Bioscience, SNIPR Biome, Lumen Bioscience, Vaxdyn, Affinivax, and Immunethep, providing you with the latest insights into innovation in antibacterial therapies.